BioMarin Pharmaceutical (BMRN) has caught plenty of eyes this week, thanks to fresh clinical data unveiled at the American Society for Bone and Mineral Research Annual Meeting. The spotlight is on VOXZOGO, BioMarin’s therapy for achondroplasia, after results showed measurable improvements in spinal anatomy and sustained benefits even in children treated after puberty began. This is not just another incremental update. By addressing spinal complications with robust clinical findings, BioMarin tackled a problem that has been short on effective solutions, which is why so many investors and medical professionals are now paying attention.

This announcement marks a turning point after what has been a challenging year for the stock. In the past twelve months, BioMarin shares are down 23%, lagging the broader biotech space, despite steady annual revenue growth and a sharp uptick in net income. Momentum remains uncertain in the near term, with the month’s decline offset only slightly by small gains over the past quarter. Earlier in the year, the company also took the stage at DPharm 2025 to share its broader patient-centered strategies. This signals an ongoing push to innovate beyond a single product story.

With shares looking beaten down after the last year but new data highlighting medical progress, the real question now is whether BioMarin represents hidden value for long-term investors or if the current price already includes all the upside from recent breakthroughs.

Most Popular Narrative: 43.7% Undervalued

The most widely followed narrative suggests BioMarin Pharmaceutical is significantly undervalued, with the current share price trading at a substantial discount to its fair value estimate.

Accelerated pipeline advancement, including late-stage programs (BMN 333 for achondroplasia, BMN 401 for ENPP1 deficiency, and label expansions for PALYNZIQ), positions BioMarin to capitalize on growing patient pools through earlier and more accurate genetic identification. This is expected to expand future addressable markets and boost revenue. Recent acquisition of Inozyme and ongoing business development initiatives broaden BioMarin's enzyme therapy portfolio and introduce new high-value therapies targeting severe unmet needs, enhancing diversification and durability of revenue streams over the long term.

Want to uncover the numbers behind this bullish outlook? The future estimate relies on bold forecasts for both earnings and profit margins, assumptions usually reserved for market leaders in breakthrough industries. What financial levers are analysts pulling to justify such a large disconnect between price and value? If you are curious about which forecasts really move the needle for BioMarin, the answers might surprise you.

Result: Fair Value of $96.59 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, intensifying competition and higher expenses from new product launches could threaten BioMarin’s growth prospects, which challenges this bullish valuation narrative.

Find out about the key risks to this BioMarin Pharmaceutical narrative.

Another View: What Does the DCF Model Tell Us?

Looking through the lens of the SWS DCF model offers a different take. This suggests BioMarin may be even further undervalued than the earlier approach indicates. But does this model paint too rosy a picture?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out BioMarin Pharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own BioMarin Pharmaceutical Narrative

If you think there is more to the story or want to dive deeper into the numbers yourself, building your own take on BioMarin’s outlook only takes a few minutes. Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding BioMarin Pharmaceutical.

Looking for More Investment Ideas?

Smart investors always stay ahead by spotting unique opportunities before the crowd. Why limit your portfolio to just one possibility? Try these high-conviction ideas and take your next step toward outperformance today.

• Spot hidden gems with strong fundamentals by starting with our list of screener containing undiscovered stocks with strong fundamentals.
• Capitalize on surging breakthroughs in artificial intelligence by checking out AI penny stocks shaping tomorrow’s tech landscape.
• Grow your income with businesses delivering strong yields and stability in our selection of dividend stocks with yields > 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.